RBC Capital maintained a Sector Perform rating on Impax Laboratories (NASDAQ: IPXL), and cut the price target to $30.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Impax Laboratories (IPXL) PT Cut to $24 at Leerink PartnersAugust 10, 2016 7:08 AM Impax Laboratories (IPXL) Misses Q2 EPS by 11c; Guides LowerAugust 9, 2016 7:05 AM Impax Reports Second Quarter 2016 Financial ResultsAugust 9, 2016 7:01 AM Trading Radar for 8/9: Disney (DIS), Coach (COH), Valeant Pharma (VRX), Wayfair (W), Yelp (YELP) ReportAugust 8, 2016 2:26 PM